Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects

Randomized Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects

The primary objective is to determine whether, during a rapid sequence intubation by etomidate, and succinylcholine Sellick maneuver, the administration of remifentanil at 2 different dosages (0.5 and 1.0 microgram per kg body weight), reduces potentially dangerous reactional tachycardia.

Inclusion Criteria:

• Patients requiring rapid sequence intubation for whatever reason. This includes the following: a full stomach, obesity, diabetic gastroparesis, gastroesophageal reflux
• Patient able to give informed consent, and sign the consent.

Exclusion Criteria:

• Contraindication for the use of any drugs used (regardless of the patient group): a history of serious side effects, allergic reaction
• Morbid obesity (Body Mass Index > 40)
• Emergency situation with unstable hemodynamics, and stabilization is impossible before induction
• Inclusion in another research project within the past 3 months
• The patient is not insured or beneficiary of a health insurance plan (for the French centers)
• Patient under guardianship of any kind
• Patient unable to give informed consent
• Refusal to sign the consent form